Biocartis

Biocartis Reports 12 Percent Rise in 2021 Revenues

In Brief This Week: Cepheid, Biocartis, Sight Diagnostics, Fluidigm, Co-Diagnostics, and More

Immunexpress Receives FDA 510(k) Clearance for Sepsis Assay

Biocartis H1 Revenues up 31 Percent

Biocartis Receives €1.4M Grant to Develop New Technology for Molecular Surveillance

Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test

Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

Biocartis Reports 15 Percent Rise in 2020 Revenues

In Brief This Week: Quotient Limited, Bio-Rad, Danaher, and More

Biocartis Q3 Cartridge Volume Grows 61 Percent

Biocartis Gets CE Mark for SARS-CoV-2 RT-PCR Test

Biocartis to Invest in IVD Partnerships Following Termination of Genomic Health Deal

Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform

Biocartis, Exact Sciences Terminate Oncotype DX Agreement

Bristol Myers Squibb, LabCorp, NeoGenomics, Others Join Consortium to Improve COVID-19 Testing

Biocartis Receives €1.2M Flemish Government Grant to Develop GeneFusion Assay on Idylla Platform

In Brief This Week: BioReference Laboratories, Biocartis, Broad Institute, and More

Biocartis H1 Revenues Drop 2 Percent